A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.


Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Administration, Intranasal
  • Animals
  • Antibodies, Viral / immunology
  • Coronavirus Nucleocapsid Proteins
  • Immunity, Cellular
  • Immunization, Secondary / methods
  • Immunoglobulin A / immunology
  • Injections, Intramuscular
  • Lipopeptides / immunology
  • Mice
  • Mice, Inbred BALB C
  • Nucleocapsid Proteins / immunology*
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Severe acute respiratory syndrome-related coronavirus / immunology*
  • Vaccinia virus / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology*


  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Coronavirus Nucleocapsid Proteins
  • Immunoglobulin A
  • Lipopeptides
  • Nucleocapsid Proteins
  • Viral Vaccines
  • macrophage stimulatory lipopeptide 2